Dihexa
also known as N-hexanoic-Tyr-Ile-(6) aminohexanoic amide
Synthetic angiotensin IV analogue that activates the hepatocyte growth factor (HGF)/c-Met receptor system, inducing dendritic arborization and synaptogenesis in rodent models. Animal studies demonstrate cognitive enhancement and synapse formation in mouse Alzheimer's models. No human clinical data available. Pre-clinical stage only.
At a glance
Not established — animal studies only
Primary target — c-Met receptor (HGF receptor tyrosine kinase).
Pathway — HGF/c-Met receptor activation → downstream signaling cascade → synaptogenesis and dendritic arborization.
Downstream effect — Induction of dendritic arborization, synapse formation, neurogenesis, and neuroprotection in rodent models.
Origin — Small-molecule angiotensin IV analogue designed to activate HGF/c-Met system [wright-2015].
| Parameter | Value |
|---|---|
| Human dosing | Not established — no human trials |
| Animal studies | Mouse/rat models only — dosing not translatable to humans |
| Evidence basis | Pre-clinical / Rodent models |
| Clinical status | No Phase 1, 2, or 3 trials published |
Reconstitution
A pure mass-to-volume utility. Enter what you have in the vial; the atlas computes the volume per dose. No prescription information.
- — Not approved for human use — research compound only
- — Theoretical contraindication: active or history of malignancy (c-Met pathway involvement in cancer)
- 01Human administration
No established protocol. Dihexa has not been tested in human subjects. Animal studies used various routes (typically subcutaneous or intraperitoneal in rodents) not translatable to clinical use.
- 02Legal status
Pre-clinical research compound. Not approved by FDA or any regulatory authority for human use.
Sources
of 28 rendered claims carry a resolvable citation.
- [benoist-2014]Benoist 2014 — The procognitive and synaptogenic effects of angiotensin IV-derived peptides are dependent on activation of the hepatocyte growth factor/c-met system.
journal, 2014 - [wright-2015]Wright 2015 — The development of small molecule angiotensin IV analogs to treat Alzheimer's and Parkinson's diseases.
journal, 2015